NASDAQ:KRBP

Kiromic BioPharma Competitors

$5.79

+0.49 (+9.25 %)

(As of 05/14/2021 12:00 AM ET)

Add

Compare

Today's Range

$4.95

▼

$5.92

50-Day Range

$5.30

▼

$9.88

52-Week Range

$4.95

▼

$18.50

Volume16,337 shs

Average Volume19,451 shs

Market Capitalization$42.46 million

P/E RatioN/A

Dividend YieldN/A

BetaN/A

Kiromic BioPharma (NASDAQ:KRBP) Vs. AGTC, FENC, GMDA, LOGC, ERYP, and INMB

Should you be buying KRBP stock or one of its competitors? Companies in the industry of "biological products, except diagnostic" are considered alternatives and competitors to Kiromic BioPharma, including Applied Genetic Technologies (AGTC), Fennec Pharmaceuticals (FENC), Gamida Cell (GMDA), LogicBio Therapeutics (LOGC), ERYTECH Pharma (ERYP), and INmune Bio (INMB).

Kiromic BioPharma vs. Applied Genetic Technologies Stock

Kiromic BioPharma (NASDAQ:KRBP) and Applied Genetic Technologies (NASDAQ:AGTC) are both small-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their valuation, analyst recommendations, earnings, risk, institutional ownership, profitability and dividends.

Profitability

This table compares Kiromic BioPharma and Applied Genetic Technologies' net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Kiromic BioPharma	N/A	N/A	N/A
Applied Genetic Technologies	N/A	-73.06%	-53.25%

Institutional & Insider Ownership

57.9% of Applied Genetic Technologies shares are owned by institutional investors. 7.5% of Applied Genetic Technologies shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Earnings & Valuation

This table compares Kiromic BioPharma and Applied Genetic Technologies' gross revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Kiromic BioPharma	N/A	N/A	N/A	N/A	N/A
Applied Genetic Technologies	$2.45 million	67.71	$-45,890,000.00	($2.17)	-1.79

Kiromic BioPharma has higher earnings, but lower revenue than Applied Genetic Technologies.

Analyst Ratings

This is a breakdown of recent ratings and price targets for Kiromic BioPharma and Applied Genetic Technologies, as reported by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Kiromic BioPharma	0	0	0	0	N/A
Applied Genetic Technologies	0	0	6	0	3.00

Applied Genetic Technologies has a consensus price target of $17.5833, suggesting a potential upside of 353.18%. Given Applied Genetic Technologies' higher possible upside, analysts plainly believe Applied Genetic Technologies is more favorable than Kiromic BioPharma.

Summary

Applied Genetic Technologies beats Kiromic BioPharma on 5 of the 7 factors compared between the two stocks.

Kiromic BioPharma vs. Fennec Pharmaceuticals Stock

Kiromic BioPharma (NASDAQ:KRBP) and Fennec Pharmaceuticals (NASDAQ:FENC) are both small-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their valuation, analyst recommendations, earnings, risk, institutional ownership, profitability and dividends.

Profitability

This table compares Kiromic BioPharma and Fennec Pharmaceuticals' net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Kiromic BioPharma	N/A	N/A	N/A
Fennec Pharmaceuticals	N/A	-84.34%	-75.51%

Institutional & Insider Ownership

53.6% of Fennec Pharmaceuticals shares are owned by institutional investors. 9.1% of Fennec Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Earnings & Valuation

This table compares Kiromic BioPharma and Fennec Pharmaceuticals' gross revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Kiromic BioPharma	N/A	N/A	N/A	N/A	N/A
Fennec Pharmaceuticals	N/A	N/A	$-12,770,000.00	($0.64)	-9.86

Analyst Ratings

This is a breakdown of recent ratings and price targets for Kiromic BioPharma and Fennec Pharmaceuticals, as reported by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Kiromic BioPharma	0	0	0	0	N/A
Fennec Pharmaceuticals	0	0	4	0	3.00

Fennec Pharmaceuticals has a consensus price target of $14.50, suggesting a potential upside of 129.79%. Given Fennec Pharmaceuticals' higher possible upside, analysts plainly believe Fennec Pharmaceuticals is more favorable than Kiromic BioPharma.

Summary

Fennec Pharmaceuticals beats Kiromic BioPharma on 4 of the 6 factors compared between the two stocks.

Kiromic BioPharma vs. Gamida Cell Stock

Kiromic BioPharma (NASDAQ:KRBP) and Gamida Cell (NASDAQ:GMDA) are both small-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their valuation, analyst recommendations, earnings, risk, institutional ownership, profitability and dividends.

Profitability

This table compares Kiromic BioPharma and Gamida Cell's net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Kiromic BioPharma	N/A	N/A	N/A
Gamida Cell	N/A	-112.47%	-65.09%

Earnings & Valuation

This table compares Kiromic BioPharma and Gamida Cell's gross revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Kiromic BioPharma	N/A	N/A	N/A	N/A	N/A
Gamida Cell	N/A	N/A	$-34,350,000.00	($1.69)	-3.84

Analyst Ratings

This is a breakdown of recent ratings and price targets for Kiromic BioPharma and Gamida Cell, as reported by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Kiromic BioPharma	0	0	0	0	N/A
Gamida Cell	0	0	5	0	3.00

Gamida Cell has a consensus price target of $20.25, suggesting a potential upside of 212.02%. Given Gamida Cell's higher possible upside, analysts plainly believe Gamida Cell is more favorable than Kiromic BioPharma.

Kiromic BioPharma vs. LogicBio Therapeutics Stock

Kiromic BioPharma (NASDAQ:KRBP) and LogicBio Therapeutics (NASDAQ:LOGC) are both small-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their valuation, analyst recommendations, earnings, risk, institutional ownership, profitability and dividends.

Earnings & Valuation

This table compares Kiromic BioPharma and LogicBio Therapeutics' gross revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Kiromic BioPharma	N/A	N/A	N/A	N/A	N/A
LogicBio Therapeutics	N/A	N/A	$-40,130,000.00	($1.78)	-2.66

Analyst Ratings

This is a breakdown of recent ratings and price targets for Kiromic BioPharma and LogicBio Therapeutics, as reported by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Kiromic BioPharma	0	0	0	0	N/A
LogicBio Therapeutics	0	0	3	0	3.00

LogicBio Therapeutics has a consensus price target of $18.50, suggesting a potential upside of 290.30%. Given LogicBio Therapeutics' higher possible upside, analysts plainly believe LogicBio Therapeutics is more favorable than Kiromic BioPharma.

Profitability

This table compares Kiromic BioPharma and LogicBio Therapeutics' net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Kiromic BioPharma	N/A	N/A	N/A
LogicBio Therapeutics	N/A	-117.64%	-76.85%

Institutional & Insider Ownership

33.8% of LogicBio Therapeutics shares are owned by institutional investors. 23.4% of LogicBio Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Summary

LogicBio Therapeutics beats Kiromic BioPharma on 4 of the 6 factors compared between the two stocks.

Kiromic BioPharma vs. ERYTECH Pharma Stock

ERYTECH Pharma (NASDAQ:ERYP) and Kiromic BioPharma (NASDAQ:KRBP) are both small-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their dividends, risk, analyst recommendations, earnings, valuation, profitability and institutional ownership.

Valuation & Earnings

This table compares ERYTECH Pharma and Kiromic BioPharma's gross revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
ERYTECH Pharma	N/A	N/A	$-70,180,000.00	($3.92)	-1.75
Kiromic BioPharma	N/A	N/A	N/A	N/A	N/A

Analyst Recommendations

This is a breakdown of current ratings and recommmendations for ERYTECH Pharma and Kiromic BioPharma, as reported by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
ERYTECH Pharma	0	0	0	0	N/A
Kiromic BioPharma	0	0	0	0	N/A

Profitability

This table compares ERYTECH Pharma and Kiromic BioPharma's net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
ERYTECH Pharma	N/A	N/A	N/A
Kiromic BioPharma	N/A	N/A	N/A

Institutional and Insider Ownership

6.5% of ERYTECH Pharma shares are owned by institutional investors. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

Summary

ERYTECH Pharma beats Kiromic BioPharma on 1 of the 1 factors compared between the two stocks.

Kiromic BioPharma vs. INmune Bio Stock

INmune Bio (NASDAQ:INMB) and Kiromic BioPharma (NASDAQ:KRBP) are both small-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their dividends, risk, analyst recommendations, earnings, valuation, profitability and institutional ownership.

Valuation & Earnings

This table compares INmune Bio and Kiromic BioPharma's gross revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
INmune Bio	N/A	N/A	$-7,680,000.00	($0.75)	-13.04
Kiromic BioPharma	N/A	N/A	N/A	N/A	N/A

Analyst Recommendations

This is a breakdown of current ratings and recommmendations for INmune Bio and Kiromic BioPharma, as reported by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
INmune Bio	0	0	5	0	3.00
Kiromic BioPharma	0	0	0	0	N/A

INmune Bio currently has a consensus target price of $21.20, suggesting a potential upside of 116.77%. Given INmune Bio's higher possible upside, equities research analysts clearly believe INmune Bio is more favorable than Kiromic BioPharma.

Profitability

This table compares INmune Bio and Kiromic BioPharma's net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
INmune Bio	N/A	-41.18%	-39.34%
Kiromic BioPharma	N/A	N/A	N/A

Institutional and Insider Ownership

7.4% of INmune Bio shares are owned by institutional investors. 58.9% of INmune Bio shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

Summary

INmune Bio beats Kiromic BioPharma on 4 of the 6 factors compared between the two stocks.